DE19703816A1 - Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung - Google Patents

Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung

Info

Publication number
DE19703816A1
DE19703816A1 DE19703816A DE19703816A DE19703816A1 DE 19703816 A1 DE19703816 A1 DE 19703816A1 DE 19703816 A DE19703816 A DE 19703816A DE 19703816 A DE19703816 A DE 19703816A DE 19703816 A1 DE19703816 A1 DE 19703816A1
Authority
DE
Germany
Prior art keywords
infusion
concentration
solutions
additives
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19703816A
Other languages
German (de)
English (en)
Inventor
Ulrich Prof Dr Speck
Gabriele D Schuhmann-Giampieri
Peter Dr Muschick
Werner Prof Dr Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE19703816A priority Critical patent/DE19703816A1/de
Publication of DE19703816A1 publication Critical patent/DE19703816A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19703816A 1996-01-25 1997-01-27 Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung Withdrawn DE19703816A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19703816A DE19703816A1 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
DE19703816A DE19703816A1 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung

Publications (1)

Publication Number Publication Date
DE19703816A1 true DE19703816A1 (de) 1997-08-07

Family

ID=7784538

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19703816A Withdrawn DE19703816A1 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung
DE59710863T Expired - Fee Related DE59710863D1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59710863T Expired - Fee Related DE59710863D1 (de) 1996-01-25 1997-01-27 Verbesserte kontrastmittenlösungen für die intravasale anwendung

Country Status (21)

Country Link
US (1) US6638913B1 (https=)
EP (1) EP0876140B1 (https=)
JP (1) JP2000505789A (https=)
KR (1) KR100505772B1 (https=)
CN (1) CN1209751A (https=)
AT (1) ATE251893T1 (https=)
AU (1) AU2150497A (https=)
BG (1) BG62913B1 (https=)
BR (1) BR9707081A (https=)
CA (1) CA2244209C (https=)
CZ (1) CZ234898A3 (https=)
DE (2) DE19703816A1 (https=)
DK (1) DK0876140T3 (https=)
ES (1) ES2208884T3 (https=)
HU (1) HUP9901355A3 (https=)
IL (1) IL124676A0 (https=)
NO (1) NO983438L (https=)
PL (1) PL328199A1 (https=)
PT (1) PT876140E (https=)
SK (1) SK101398A3 (https=)
WO (1) WO1997026862A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7419683B2 (en) 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
CA2326777C (en) 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CA2524323C (en) 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MXPA06011419A (es) 2004-04-01 2007-04-20 Cardiome Pharma Corp Profarmacos de compuestos moduladores de canales ionicos y usos de los mismos.
ES2483940T3 (es) 2004-11-08 2014-08-08 Cardiome Pharma Corp. Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
AR076640A1 (es) 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
US10634741B2 (en) * 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CN105283202B (zh) 2013-03-11 2019-04-23 安都磁学有限公司 用于淋巴结检测的低渗溶液
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
MX2015013658A (es) * 2013-03-27 2016-02-18 Ge Healthcare As Metodo y reactivo para preparar una composicion diagnostica.
ES2833377T3 (es) 2015-06-04 2021-06-15 Endomagnetics Ltd Materiales marcadores y formas de localizar un marcador magnético
AU2019254483B2 (en) * 2018-04-16 2025-02-27 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2039223A1 (de) * 1969-08-06 1971-02-18 Beecham Group Ltd Desensibilisierungsmittel gegen Allergien und Verfahren zu seiner Herstellung
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
US4663166A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vivo use thereof
WO1990011094A1 (en) * 1989-03-17 1990-10-04 Nycomed As Contrast media
DE4135193C1 (https=) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
WO1994014478A1 (en) * 1992-12-24 1994-07-07 Bracco S.P.A. Aqueous injectable formulations useful for radio-diagnosis comprising iodinated aromatic compounds used as x-ray contrast media
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523295B2 (en) * 1978-07-04 1982-07-22 Nycomed Imaging As X-ray contrast agent
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
EP0437662B1 (de) 1990-01-18 1994-09-14 Cereria Amos Sgarbi S.P.A. Grablicht
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2039223A1 (de) * 1969-08-06 1971-02-18 Beecham Group Ltd Desensibilisierungsmittel gegen Allergien und Verfahren zu seiner Herstellung
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
US4663166A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vivo use thereof
EP0185759B1 (en) * 1984-06-22 1992-11-19 VEECH, Richard L. Electrolyte solutions and (in vivo) use thereof
WO1990011094A1 (en) * 1989-03-17 1990-10-04 Nycomed As Contrast media
DE4135193C1 (https=) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
WO1994014478A1 (en) * 1992-12-24 1994-07-07 Bracco S.P.A. Aqueous injectable formulations useful for radio-diagnosis comprising iodinated aromatic compounds used as x-ray contrast media
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.L.Miller, Current Patterns of Use, Radiology 172(1989) S.1007-1001 *
D.M.A.Jackson and P.Dawson, Clinical Radiology 50 (1995) S.699-704 *
S.H.Kim et al., Investigative Radiology 27 (1992) S.45-49 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration

Also Published As

Publication number Publication date
BR9707081A (pt) 1999-05-25
PT876140E (pt) 2004-02-27
CA2244209A1 (en) 1997-07-31
HUP9901355A2 (hu) 1999-08-30
WO1997026862A2 (de) 1997-07-31
CA2244209C (en) 2007-10-23
ATE251893T1 (de) 2003-11-15
NO983438L (no) 1998-09-18
DK0876140T3 (da) 2003-12-15
WO1997026862A3 (de) 1997-10-23
KR100505772B1 (ko) 2005-10-25
EP0876140B1 (de) 2003-10-15
EP0876140A2 (de) 1998-11-11
US6638913B1 (en) 2003-10-28
BG62913B1 (bg) 2000-11-30
DE59710863D1 (de) 2003-11-20
ES2208884T3 (es) 2004-06-16
SK101398A3 (en) 1998-12-02
PL328199A1 (en) 1999-01-18
HUP9901355A3 (en) 2000-06-28
KR19990081979A (ko) 1999-11-15
NO983438D0 (no) 1998-07-24
CZ234898A3 (cs) 1998-11-11
CN1209751A (zh) 1999-03-03
BG102644A (bg) 1999-06-30
IL124676A0 (en) 1998-12-06
AU2150497A (en) 1997-08-20
JP2000505789A (ja) 2000-05-16

Similar Documents

Publication Publication Date Title
EP0876140B1 (de) Verbesserte kontrastmittenlösungen für die intravasale anwendung
AT408720B (de) Parenterale pharmazeutische formulierung eines humaninsulinanalogon-komplexes
EP0357978B1 (de) Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE3734835A1 (de) Arzneimittel zur ophthalmologischen anwendung
DE10114178A1 (de) Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE69008258T2 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
DE60305687T2 (de) Wässrige injizierbare Suspensionen für Tiere enthaltend Florfenicol
EP1206244B1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
EP2421522B1 (de) Paracetamol zur parenteralen verabreichung
EP0885613A1 (de) Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE2658237A1 (de) Arzneimittel zur injektion in die zwischenwirbelscheiben des rueckgrats zur linderung von rueckenschmerzen und sonstiger unerwuenschter symptome
DE60001489T2 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
DE69232409T2 (de) Ungepufferte, vorgemischte ranitidin-formulierung
EP0458939B1 (de) t-PA pro STABILISIERUNG
DE4425280C2 (de) Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
DE19859910C2 (de) Orales Arzneimittel
EP0458929B1 (de) t-PA-Solubilisierung
EP0458949B1 (de) Stabilisierung von k1k2p pro
DE2657381C2 (de) Glucosehaltige Infusionslösung
DE102006031175A1 (de) Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DD291924A5 (de) Verfahren zur herstellung einer waessrigen loesung eines pentamidinsalzes
DE932146C (de) Verfahren zur Herstellung von stabilisierten, waessrigen Hyaluronidase-Loesungen
DE20023651U1 (de) Eine stabile Interferon-Formulierung in Form einer wässrigen Lösung
AU763521B2 (en) Improved concentrated injection and infusion solutions for intravascular use

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
OR8 Request for search as to paragraph 43 lit. 1 sentence 1 patent law
8105 Search report available
8125 Change of the main classification

Ipc: A61K 33/14

8130 Withdrawal